Costa Rica’s social security fund is running technical studies to choose a GLP-1 molecule for patients with diabetes, with obesity to follow. A diabetes decision is expected in November, as Wegovy enters the private market and a two-year deadline set by a 2025 decree to make obesity medicines available runs …

MARKET ACCESS · GLP-1 COVERAGE · NOVEMBER 2, 2026 · COSTA RICA
Costa Rica’s Social Security Fund (Caja Costarricense de Seguro Social, CCSS) is running technical studies to decide which GLP-1 drug would best suit it, its Medical Management division told La Nación, which reported the review on October 19. Diabetes would come first; obesity would follow. The CCSS has not said which drugs it would cover, for whom or from when, but Teletica reported that a decision on diabetes is expected in November.
300,000
Approximate number of CCSS patients with diabetes, per Teletica; a positive decision would not mean automatic access for all.
What the CCSS has said
“Our institution is carrying out the technical studies to assess which of all the GLP-1 molecules registered with the Ministry of Health is the most suitable for the institution, and to serve, in a first phase, the diabetic population for glycemic control and the diabetic population with obesity,” the Medical Management division, headed on an interim basis by Dr. Marvin Palma Lostalo, said in reply to La Nación (HealthSignals translation). His six-month interim appointment, which began May 8, is due to lapse in early November, according to the CCSS.
Teletica reported on October 26 that the review began about a year ago. Hugo Marín Piva, the CCSS’s head of pharmacoeconomics, told the broadcaster it must still settle which patients could benefit, which active ingredients to use, under what clinical criteria and at what cost. If diabetes coverage goes ahead, a separate evaluation would assess whether weight-loss use is viable.
On October 26 the CCSS replaced its Official Medicines List (Lista Oficial de Medicamentos, LOM) with an Institutional Therapeutic Formulary (Formulario Terapéutico Institucional, FTI). Under the new rules, the Health Technology Assessment Committee (Comité de Evaluación de Tecnologías Sanitarias, CETS), at work since 2025 and now including patient representatives, is the entry point for new drugs, La Nación reported. The CCSS has not publicly said whether the GLP-1 review will go through it.
The private market it would replace
Treatment in private pharmacies costs roughly ₡50,000 to ₡200,000 a month, depending on drug and dose, according to prices La Nación gathered from private pharmacies, with Mounjaro at the top end. That is about $110 to $439 at the Central Bank of Costa Rica (Banco Central de Costa Rica, BCCR) reference selling rate of ₡455.44 per dollar on October 30, 2026. Novo Nordisk said Wegovy (semaglutide) became available on October 13; La Nación found it at ₡49,995 (0.25 mg) to ₡178,995 (2.4 mg). On July 22, the Ministry of Health warned against unregistered semaglutide, tirzepatide and liraglutide products sold on social media; at the time the only registered products containing those molecules were Ozempic, Saxenda and Mounjaro KwikPen. Wegovy has since been registered, La Nación reported.
About 42% of Costa Rican adults are overweight and 32% obese, according to CCSS figures cited by The Tico Times. Decree 44780-S, published on January 8, 2025, declared obesity a chronic disease of public-health importance, made a national obesity care standard mandatory and, according to La Nación, gave public, private and mixed health services two years to make obesity medicines available to patients.
Regional precedent
Brazil said no in 2025. On September 15 that year its Ministry of Health decided not to add semaglutide (for high-risk obesity without diabetes) or liraglutide (for obesity with type 2 diabetes) to the Unified Health System (Sistema Único de Saúde, SUS). It is now looking again. Novo Nordisk filed a new semaglutide request in June 2026 offering a 59% discount on the reference price, Deutsche Welle reported via G1. On September 24 the ministry itself asked the National Commission for the Incorporation of Technologies into the SUS (Comissão Nacional de Incorporação de Tecnologias no SUS, Conitec) to assess off-patent semaglutide and liraglutide for obesity. In September 2025, WHO added semaglutide, dulaglutide, liraglutide and tirzepatide to its Model List of Essential Medicines for adults with type 2 diabetes with established cardiovascular disease or chronic kidney disease and obesity.
What to Watch
- The CCSS decision on GLP-1s for diabetes expected in November 2026, and which molecule it picks
- Whether the CCSS meets January 2027, when patient groups, citing the national obesity care standard, say it must offer drug treatment
- Whether the obesity-only phase goes before the CETS, with patient representatives in the room
Sources: La Nación: CCSS evalúa utilizar las terapias GLP-1 para tratar la obesidad · La Nación: CCSS estudia cuál molécula GLP-1 es más conveniente · The Tico Times: Costa Rica’s Public Healthcare System Considers Offering Ozempic and Other Weight-Loss Drugs · Teletica: Salud registra 695 reportes de presuntas reacciones adversas · La Nación: CCSS encuentra una forma para acercar más medicamentos · La Nación: Wegovy ya está disponible en Costa Rica · Ministry of Health: Advertencia sanitaria sobre semaglutida, tirzepatida y liraglutida · Teletica: Tratamientos para la obesidad deberán estar disponibles en la CCSS en enero de 2027 · La Nación: Costa Rica declara la obesidad como enfermedad crónica · Ministry of Health: Decreto 44780-S · BCCR: Reference exchange rate · Brazil: Portaria SECTICS/MS 65 of 2025 · Brazil: Portaria SECTICS/MS 67 of 2025 · Deutsche Welle via G1: Por que o SUS não distribui nenhum tipo de caneta emagrecedora · Brazil Ministry of Health: pedido à Conitec sobre canetas emagrecedoras · CCSS: Marvin Palma Lostalo, gerente médico interino · WHO: Updated Essential Medicines List
Related coverage
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







